Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of endoscopic dacryocystorhinostomy using Markov modelling.
Hu, Jenny Q; Men, Clara J; Afshari, Natalie A; Liu, Catherine Y; Korn, Bobby S; Kikkawa, Don O.
Afiliação
  • Hu JQ; Shiley Eye Institute, University of California San Diego, La Jolla, CA. Electronic address: jqh003@health.ucsd.edu.
  • Men CJ; Byers Eye Institute, Stanford University, Palo Alto, CA.
  • Afshari NA; Shiley Eye Institute, University of California San Diego, La Jolla, CA.
  • Liu CY; Shiley Eye Institute, University of California San Diego, La Jolla, CA; Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, University of California San Diego, La Jolla, CA.
  • Korn BS; Shiley Eye Institute, University of California San Diego, La Jolla, CA; Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, University of California San Diego, La Jolla, CA; Division of Plastic Surgery, Department of Surgery, University of California San Diego, L
  • Kikkawa DO; Shiley Eye Institute, University of California San Diego, La Jolla, CA; Division of Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, University of California San Diego, La Jolla, CA; Division of Plastic Surgery, Department of Surgery, University of California San Diego, L
Can J Ophthalmol ; 2023 Mar 28.
Article em En | MEDLINE | ID: mdl-37001560
ABSTRACT

OBJECTIVE:

To determine the cost-effectiveness of endoscopic dacryocystorhinostomy (DCR).

METHODS:

We constructed a Markov model in which patients with nasolacrimal duct obstruction received endoscopic DCR or no surgery. Incremental cost-effectiveness ratios, 1-way sensitivity analyses, and probabilistic sensitivity analyses were used to evaluate for model sensitivity to multiple model inputs.

RESULTS:

Endoscopic DCR was found to be cost-effective with an incremental cost-effectiveness ratio of US$2162 per quality-adjusted life-year. The model was most sensitive to the health utility deduction from epiphora. Probabilistic sensitivity analysis found endoscopic DCR to be cost-effective over no surgery 93.7% of the time.

CONCLUSIONS:

Endoscopic DCR is a cost-effective treatment for patients with epiphora. The model is very sensitive to the negative effect epiphora has on quality of life. With the advancement of health care technology and surgical techniques, the success rates of endoscopic DCR continue to improve and to be an even more efficacious and economical treatment for nasolacrimal duct obstruction.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2023 Tipo de documento: Article